These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22817470)

  • 1. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.
    Lambourne MD; Eltringham-Smith LJ; Gataiance S; Arnold DM; Crowther MA; Sheffield WP
    J Thromb Haemost; 2012 Sep; 10(9):1830-40. PubMed ID: 22817470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
    Grottke O; van Ryn J; Spronk HM; Rossaint R
    Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage.
    Frontera JA; Gordon E; Zach V; Jovine M; Uchino K; Hussain MS; Aledort L
    Neurocrit Care; 2014 Dec; 21(3):397-406. PubMed ID: 24671832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department.
    Maguire M; Fuh L; Goldstein JN; Marshall AL; Levine M; Howell ML; Parry BA; Rosovsky R; Hayes BD
    West J Emerg Med; 2019 Jul; 20(4):619-625. PubMed ID: 31316701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
    Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
    Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin-induced bleeding complications - clinical presentation and therapeutic options.
    Wiedermann CJ; Stockner I
    Thromb Res; 2008; 122 Suppl 2():S13-8. PubMed ID: 18549907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
    Sheffield WP; Lambourne MD; Eltringham-Smith LJ; Bhakta V; Arnold DM; Crowther MA
    J Thromb Haemost; 2014 Jul; 12(7):1110-5. PubMed ID: 24815541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Fresh-Frozen Plasma, Four-Factor Prothrombin Complex Concentrates, and Recombinant Factor VIIa to Facilitate Procedures in Critically Ill Patients with Coagulopathy from Liver Disease: A Retrospective Cohort Study.
    Kwon JO; MacLaren R
    Pharmacotherapy; 2016 Oct; 36(10):1047-1054. PubMed ID: 27547916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography.
    Won SY; Schlunk F; Dinkel J; Karatas H; Leung W; Hayakawa K; Lauer A; Steinmetz H; Lo EH; Foerch C; Gupta R
    Stroke; 2013 Oct; 44(10):2883-90. PubMed ID: 23920016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study.
    Sølbeck S; Nilsson CU; Engström M; Ostrowski SR; Johansson PI
    Scand J Clin Lab Invest; 2014 Oct; 74(7):591-8. PubMed ID: 24909158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.
    van Ryn J; Schurer J; Kink-Eiband M; Clemens A
    Anesthesiology; 2014 Jun; 120(6):1429-40. PubMed ID: 24714118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage.
    Yanamadala V; Walcott BP; Fecci PE; Rozman P; Kumar JI; Nahed BV; Swearingen B
    J Clin Neurosci; 2014 Nov; 21(11):1881-4. PubMed ID: 24953825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prothrombin complex concentrate accelerates international normalized ratio reversal and diminishes the extension of intracranial hemorrhage in geriatric trauma patients.
    Edavettal M; Rogers A; Rogers F; Horst M; Leng W
    Am Surg; 2014 Apr; 80(4):372-6. PubMed ID: 24887668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
    van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
    Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
    Perzborn E; Gruber A; Tinel H; Marzec UM; Buetehorn U; Buchmueller A; Heitmeier S; Laux V
    Thromb Haemost; 2013 Jul; 110(1):162-72. PubMed ID: 23636219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.